High CCR6/CCR7 expression and Foxp3+ Treg cell number are positively related to the progression of laryngeal squamous cell carcinoma

Chen,Bin; Zhang,Duo; Zhou,Jian; Li,Qing; Zhou,Lin; Li,Shi-Min; Zhu,Li; Chou,Kuang-Yen; Zhou,Liang; Tao,Lei; Lu,Li-Ming

doi:10.3892/or.2013.2603

High CCR6/CCR7 expression and Foxp3+ Treg cell number are positively related to the progression of laryngeal squamous cell carcinoma

Authors:
- Bin Chen
- Duo Zhang
- Jian Zhou
- Qing Li
- Lin Zhou
- Shi-Min Li
- Li Zhu
- Kuang-Yen Chou
- Liang Zhou
- Lei Tao
- Li-Ming Lu
View Affiliations

Affiliations: Department of Otolaryngology, Eye Ear Nose and Throat Hospital, Fudan University, Shanghai 200031, P.R. China, Shanghai Institute of Immunology, Shanghai Jiaotong University School of Medicine, Shanghai 200025, P.R. China, Department of Pathology, Eye Ear Nose and Throat Hospital, Fudan University, Shanghai 200031, P.R. China
Published online on: July 8, 2013 https://doi.org/10.3892/or.2013.2603
Pages: 1380-1390

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Chemokine receptors CCR6 and CCR7 have been reported to play important roles in T cell migration and organ-specific metastasis of various tumors. In the present study, we evaluated the expression and clinical significance of CCR6, CCR7, their ligands and CD4+CD25+Foxp3+ regulatory T cells in laryngeal squamous cell carcinoma (LSCC) and metastatic lymph nodes (LNs). The expression of CCR6, CCR7 and their ligands mRNA (CCL20, CCL19/CCL21) as well as the CCR6 and CCR7 proteins were detected by real-time RT-PCR and immunohistochemistry (IHC), respectively. Flow cytometry was used to investigate the percentage of CD4+CD25+Foxp3+ regulatory T cells (Tregs) in peripheral blood mononuclear cells (PBMCs). Furthermore, a number of cytokines, including interleukin (IL)-2, IL-4, IL-10, IL-12p70, interferon (IFN)-γ and transforming growth factor (TGF)-β1 were detected by ELISA. The results showed that CCR6 and CCR7 were expressed in tumors in situ, metastatic LNs and CD4+CD25+Foxp3+ Tregs. It was hypothesized that the expression profile of CCR6, CCR7 and the proliferation of CD4+CD25+Foxp3+ Tregs affected the process of LN metastasis in LSCC patients. Therefore, the increased percentage of the Foxp3+ Tregs and the upregulation of Foxp3 expression on CCR6+ Tregs in LSCC patients may have accounted for the downregulation of antitumor immunity in these patients, which could be valuable for assessment of prognosis in LSCC treatment.

View Figures

View References

1	Marioni G, Marchese-Ragona R, Cartei G, Marchese F and Staffieri A: Current opinion in diagnosis and treatment of laryngeal carcinoma. Cancer Treat Rev. 32:504–515. 2006. View Article : Google Scholar : PubMed/NCBI
2	Hoffman HT, Porter K, Karnell LH, et al: Laryngeal cancer in the United States: changes in demographics, patterns of care, and survival. Laryngoscope. 116:1–13. 2006. View Article : Google Scholar : PubMed/NCBI
3	Shah JP, Karnell LH, Hoffman HT, et al: Patterns of care for cancer of the larynx in the United States. Arch Otolaryngol Head Neck Surg. 123:475–483. 1997. View Article : Google Scholar : PubMed/NCBI
4	Alhamarneh O, Agada F, Madden L, Stafford N and Greenman J: Serum IL10 and circulating CD4(+) CD25(high) regulatory T cell numbers as predictors of clinical outcome and survival in patients with head and neck squamous cell carcinoma. Head Neck. 33:415–423. 2011.
5	Whiteside TL: The tumor microenvironment and its role in promoting tumor growth. Oncogene. 27:5904–5912. 2008. View Article : Google Scholar : PubMed/NCBI
6	Zou W: Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol. 6:295–307. 2006. View Article : Google Scholar : PubMed/NCBI
7	Roncarolo MG, Bacchetta R, Bordignon C, Narula S and Levings MK: Type 1 T regulatory cells. Immunol Rev. 182:68–79. 2001. View Article : Google Scholar : PubMed/NCBI
8	Dieckmann D, Plottner H, Berchtold S, Berger T and Schuler G: Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood. J Exp Med. 193:1303–1310. 2001.
9	Jonuleit H, Schmitt E, Stassen M, Tuettenberg A, Knop J and Enk AH: Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood. J Exp Med. 193:1285–1294. 2001.
10	Levings MK, Sangregorio R and Roncarolo MG: Human cd25(+)cd4(+) T regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J Exp Med. 193:1295–1302. 2001.
11	Chen Y, Kuchroo VK, Inobe J, Hafler DA and Weiner HL: Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science. 265:1237–1240. 1994. View Article : Google Scholar : PubMed/NCBI
12	Sakaguchi S, Yamaguchi T, Nomura T and Ono M: Regulatory T cells and immune tolerance. Cell. 133:775–787. 2008. View Article : Google Scholar : PubMed/NCBI
13	Sakaguchi S, Miyara M, Costantino CM and Hafler DA: Foxp3⁺ regulatory T cells in the human immune system. Nat Rev Immunol. 10:490–500. 2010.
14	Xu L, Xu W, Wen Z and Xiong S: In situ prior proliferation of CD4⁺ CCR6⁺ regulatory T cells facilitated by TGF-β secreting DCs is crucial for their enrichment and suppression in tumor immunity. PLoS One. 6:e202822011.PubMed/NCBI
15	Wei S, Kryczek I and Zou W: Regulatory T-cell compartmentalization and trafficking. Blood. 108:426–431. 2006. View Article : Google Scholar : PubMed/NCBI
16	Zhu J and Paul WE: CD4 T cells: fates, functions, and faults. Blood. 112:1557–1569. 2008. View Article : Google Scholar : PubMed/NCBI
17	Mburu YK, Wang J, Wood MA, Walker WH and Ferris RL: CCR7 mediates inflammation-associated tumor progression. Immunol Res. 36:61–72. 2006. View Article : Google Scholar : PubMed/NCBI
18	Schutyser E, Struyf S and Van Damme J: The CC chemokine CCL20 and its receptor CCR6. Cytokine Growth Factor Rev. 14:409–426. 2003. View Article : Google Scholar : PubMed/NCBI
19	Zlotnik A and Yoshie O: Chemokines: a new classification system and their role in immunity. Immunity. 12:121–127. 2000. View Article : Google Scholar : PubMed/NCBI
20	Hirahara K, Liu L, Clark RA, Yamanaka K, Fuhlbrigge RC and Kupper TS: The majority of human peripheral blood CD4⁺CD25^highFoxp3⁺ regulatory T cells bear functional skin-homing receptors. J Immunol. 177:4488–4494. 2006.PubMed/NCBI
21	Wang J, Xi L, Hunt JL, et al: Expression pattern of chemokine receptor 6 (CCR6) and CCR7 in squamous cell carcinoma of the head and neck identifies a novel metastatic phenotype. Cancer Res. 64:1861–1866. 2004. View Article : Google Scholar : PubMed/NCBI
22	Arya M, Patel HR and Williamson M: Chemokines: key players in cancer. Curr Med Res Opin. 19:557–564. 2003. View Article : Google Scholar
23	Vinader V and Afarinkia K: A beginner’s guide to chemokines. Future Med Chem. 4:845–852. 2012.
24	Tetu B, Popa I, Bairati I, et al: Immunohistochemical analysis of possible chemoresistance markers identified by micro-arrays on serous ovarian carcinomas. Mod Pathol. 21:1002–1010. 2008. View Article : Google Scholar : PubMed/NCBI
25	Waugh DJ and Wilson C: The interleukin-8 pathway in cancer. Clin Cancer Res. 14:6735–6741. 2008. View Article : Google Scholar : PubMed/NCBI
26	Müller A, Homey B, Soto H, et al: Involvement of chemokine receptors in breast cancer metastasis. Nature. 410:50–56. 2001.PubMed/NCBI
27	Forster R, Davalos-Misslitz AC and Rot A: CCR7 and its ligands: balancing immunity and tolerance. Nat Rev Immunol. 8:362–371. 2008. View Article : Google Scholar : PubMed/NCBI
28	Mantovani A, Savino B, Locati M, Zammataro L, Allavena P and Bonecchi R: The chemokine system in cancer biology and therapy. Cytokine Growth Factor Rev. 21:27–39. 2010. View Article : Google Scholar
29	Ghadjar P, Coupland SE, Na IK, et al: Chemokine receptor CCR6 expression level and liver metastases in colorectal cancer. J Clin Oncol. 24:1910–1916. 2006. View Article : Google Scholar : PubMed/NCBI
30	Wittekind C, Compton CC, Greene FL and Sobin LH: TNM residual tumor classification revisited. Cancer. 94:2511–2516. 2002. View Article : Google Scholar : PubMed/NCBI
31	Pavelic ZP, Pavelic K, Carter CP and Pavelic L: Heterogeneity of c-myc expression in histologically similar infiltrating ductal carcinomas of the breast. J Cancer Res Clin Oncol. 118:16–22. 1992. View Article : Google Scholar : PubMed/NCBI
32	Tao L, Zhou L, Zheng L and Yao M: Elemene displays anti-cancer ability on laryngeal cancer cells in vitro and in vivo. Cancer Chemother Pharmacol. 58:24–34. 2006. View Article : Google Scholar : PubMed/NCBI
33	Lefebvre JL and Ang KK: Larynx preservation clinical trial design: key issues and recommendations - a consensus panel summary. Head Neck. 31:429–441. 2009. View Article : Google Scholar
34	Chen AY, Schrag N, Hao Y, et al: Changes in treatment of advanced laryngeal cancer 1985–2001. Otolaryngol Head Neck Surg. 135:831–837. 2006.
35	Holsinger FC and Weber RS: Swing of the surgical pendulum: a return to surgery for treatment of head and neck cancer in the 21st century? Int J Radiat Oncol Biol Phys. 69(Suppl 2): S129–S131. 2007. View Article : Google Scholar : PubMed/NCBI
36	Laccourreye O, Brasnu D, Bassot V, Menard M, Khayat D and Laccourreye H: Cisplatin-fluorouracil exclusive chemotherapy for T1-T3N0 glottic squamous cell carcinoma complete clinical responders: five-year results. J Clin Oncol. 14:2331–2336. 1996.
37	Lefebvre JL, Rolland F, Tesselaar M, et al: Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy. J Natl Cancer Inst. 101:142–152. 2009. View Article : Google Scholar : PubMed/NCBI
38	Stenson KM, Maccracken E, Kunnavakkam R, et al: Chemoradiation for patients with large-volume laryngeal cancers. Head Neck. 34:1162–1167. 2012.PubMed/NCBI
39	Beider K, Abraham M, Begin M, et al: Interaction between CXCR4 and CCL20 pathways regulates tumor growth. PLoS One. 4:e51252009. View Article : Google Scholar : PubMed/NCBI
40	Bonnotte B, Crittenden M, Larmonier N, Gough M and Vile RG: MIP-3alpha transfection into a rodent tumor cell line increases intratumoral dendritic cell infiltration but enhances (facilitates) tumor growth and decreases immunogenicity. J Immunol. 173:4929–4935. 2004. View Article : Google Scholar
41	Cabioglu N, Yazici MS, Arun B, et al: CCR7 and CXCR4 as novel biomarkers predicting axillary lymph node metastasis in T1 breast cancer. Clin Cancer Res. 11:5686–5693. 2005. View Article : Google Scholar : PubMed/NCBI
42	Shang ZJ, Liu K and Shao Z: Expression of chemokine receptor CCR7 is associated with cervical lymph node metastasis of oral squamous cell carcinoma. Oral Oncol. 45:480–485. 2009. View Article : Google Scholar : PubMed/NCBI
43	Takanami I: Overexpression of CCR7 mRNA in nonsmall cell lung cancer: correlation with lymph node metastasis. Int J Cancer. 105:186–189. 2003. View Article : Google Scholar : PubMed/NCBI
44	Chen KJ, Lin SZ, Zhou L, et al: Selective recruitment of regulatory T cell through CCR6-CCL20 in hepatocellular carcinoma fosters tumor progression and predicts poor prognosis. PLoS One. 6:e246712011. View Article : Google Scholar : PubMed/NCBI
45	Annunziato F, Cosmi L, Liotta F, et al: Phenotype, localization, and mechanism of suppression of CD4(+)CD25(+) human thymocytes. J Exp Med. 196:379–387. 2002.
46	Iellem A, Mariani M, Lang R, et al: Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T cells. J Exp Med. 194:847–853. 2001.PubMed/NCBI
47	Xu L, Xu W, Qiu S and Xiong S: Enrichment of CCR6⁺Foxp3⁺ regulatory T cells in the tumor mass correlates with impaired CD8⁺ T cell function and poor prognosis of breast cancer. Clin Immunol. 135:466–475. 2010.PubMed/NCBI
48	Kosmaczewska A, Ciszak L, Potoczek S and Frydecka I: The significance of Treg cells in defective tumor immunity. Arch Immunol Ther Exp (Warsz). 56:181–191. 2008. View Article : Google Scholar : PubMed/NCBI
49	Mao C, Wang S, Jiang Q, et al: Increased CD4⁺CD25⁺Foxp3⁺ regulatory T cells in cancer patients from conversion of CD4⁺CD25⁻ T cells through tumor-derived factors. Onkologie. 31:243–248. 2008.
50	Pakravan N, Hassan AT and Hassan ZM: Naturally occurring self-reactive CD4⁺CD25⁺ regulatory T cells: universal immune code. Cell Mol Immunol. 4:197–201. 2007.
51	Strauss L, Bergmann C, Szczepanski M, Gooding W, Johnson JT and Whiteside TL: A unique subset of CD4⁺CD25^highFoxp3⁺ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment. Clin Cancer Res. 13:4345–4354. 2007.PubMed/NCBI
52	Sakaguchi S: Naturally arising Foxp3-expressing CD25⁺CD4⁺ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol. 6:345–352. 2005. View Article : Google Scholar : PubMed/NCBI
53	Ebert LM, Tan BS, Browning J, et al: The regulatory T cell-associated transcription factor FoxP3 is expressed by tumor cells. Cancer Res. 68:3001–3009. 2008. View Article : Google Scholar : PubMed/NCBI
54	Karanikas V, Speletas M, Zamanakou M, et al: Foxp3 expression in human cancer cells. J Transl Med. 6:192008. View Article : Google Scholar : PubMed/NCBI
55	Ladoire S, Arnould L, Mignot G, et al: Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy. Breast Cancer Res Treat. 125:65–72. 2011. View Article : Google Scholar
56	O’Hayre M, Salanga CL, Handel TM and Allen SJ: Chemokines and cancer: migration, intracellular signalling and intercellular communication in the microenvironment. Biochem J. 409:635–649. 2008.PubMed/NCBI
57	Ito S, Ozawa S, Ikoma T, Yajima N, Kiyono T and Hata R: Expression of a chemokine BRAK/CXCL14 in oral floor carcinoma cells reduces the settlement rate of the cells and suppresses their proliferation in vivo. Biomed Res. 31:199–206. 2010. View Article : Google Scholar : PubMed/NCBI
58	Silva TA, Ribeiro FL, Oliveira-Neto HH, et al: Dual role of CCL3/CCR1 in oral squamous cell carcinoma: Implications in tumor metastasis and local host defense. Oncol Rep. 18:1107–1113. 2007.PubMed/NCBI
59	Sakaguchi S, Sakaguchi N, Asano M, Itoh M and Toda M: Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 155:1151–1164. 1995.
60	DiPersio JF, Micallef IN, Stiff PJ, et al: Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin’s lymphoma. J Clin Oncol. 27:4767–4773. 2009.PubMed/NCBI